Madrigal (MDGL) Director John C. Reed Receives Equity Awards

What Happened
John C. Reed, a director of Madrigal Pharmaceuticals (MDGL), was granted equity awards on August 15, 2026: 647 restricted stock units (RSUs) and 1,078 derivative awards recorded at $0.00 (no cash paid). These are compensation awards (not open-market purchases or sales) and do not represent immediate cash proceeds.

Key Details

• Transaction date: August 15, 2026. Report filed August 18, 2026. (Form 4s are typically due within two business days of the transaction; this filing was three days after the grant—check timeliness.)
• Award amounts and prices: 647 RSUs @ $0.00; 1,078 derivative shares @ $0.00.
• Shares owned after the transaction: not reported in the provided filing summary.
• Footnotes:
  • F1 (647 RSUs): Vesting as to 50% on Aug 15, 2027 and 50% on Aug 15, 2028, contingent on continued service.
  • F2 (1,078 derivative award): Vests 50% on Aug 15, 2027, then 12.5% at the end of each successive three‑month period for four quarters thereafter, contingent on continued service.
• No indication in this filing of sales, gifts, tax withholding, or a 10b5-1 plan.

Context
These are standard director compensation awards that vest over time and do not imply an immediate purchase or sale of shares. Because of the multi-year vesting schedules, the awards provide future equity alignment with the company but are not immediately liquid. The 1,078-unit derivative award follows a time-based vesting schedule (described above) rather than an immediate exercise-and-sell action.